By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539


SEARCH JOBS
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Key Statistics


Email: hr@halozyme.com
Ownership: Public

Web Site: Halozyme Therapeutics, Inc.
Employees: 152
Symbol: HALO
 









Company News
Halozyme Therapeutics, Inc. (HALO) Reports Fourth Quarter And Full Year 2014 Financial Results 3/3/2015 8:42:13 AM
Halozyme Therapeutics, Inc. (HALO) To Host Fourth Quarter And 2014 Year-End Financial Results Conference Call 2/24/2015 7:36:29 AM
Halozyme Therapeutics, Inc. (HALO) Announces Preclinical Study Results Of Pegph20 Published In Molecular Cancer Therapeutics 2/17/2015 7:52:12 AM
Halozyme Therapeutics, Inc. (HALO) Appoints Jean-Pierre Bizzari, M.D. To Board Of Directors 1/21/2015 10:18:49 AM
Halozyme Therapeutics, Inc. (HALO) Provides An Update On Anticipated Milestones For 2015 At The 33rd Annual J. P. Morgan Healthcare Conference 1/12/2015 9:55:58 AM
Halozyme Therapeutics, Inc. (HALO) Provides Agenda Highlights For Analyst And Investor Meeting 1/7/2015 8:55:06 AM
Halozyme Therapeutics, Inc. (HALO) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/6/2015 10:56:37 AM
Halozyme Therapeutics, Inc. (HALO) Appoints Athena Countouriotis, M.D. As Chief Medical Officer 1/5/2015 8:35:02 AM
Halozyme Therapeutics, Inc. (HALO) To Host Analyst And Investor Meeting 12/30/2014 7:35:23 AM
Halozyme Therapeutics, Inc. (HALO) Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer 12/19/2014 8:41:41 AM
12345678910...
//-->